Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sandoz Group
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports first quarter 2024 sales
May 07, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
March 13, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz announces nominations to the Board of Directors and leadership change
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
February 29, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz announces changes in the Board of Directors
February 01, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
January 31, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
January 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
November 21, 2023
From
Sandoz Group
Via
GlobeNewswire
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
November 10, 2023
From
Sandoz Group
Via
GlobeNewswire
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
November 08, 2023
From
Sandoz Group
Via
GlobeNewswire
Sandoz successfully issues CHF 750 million in inaugural bonds
October 26, 2023
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports year-to-date sales for the first nine months of 2023
October 24, 2023
From
Sandoz Group
Via
GlobeNewswire
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
October 04, 2023
From
Sandoz Group
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.